The Algeta story
A Norwegian company with global vision, Algeta aims to bring benefit to cancer patients in areas of high need. Key to realizing its goal of becoming a global oncology company has been in having the right technology, capacity, and people to deliver.
Ten years ago, Algeta had less than 10 employees who did everything – clinical trials, research and development, production, quality control, management, finances. They faced the same regulatory requirements as big pharmaceutical companies, and have grown the company by recruiting a talented team from across the world.
With studies of its experimental alpha-pharmaceutical product radium-223 dichloride (radium-223) demonstrating improvements in patients’ overall survival compared to placebo, the next stage of growth sees Algeta focusing on how to grow the company’s US commercial operations.
"We are seeking to create meaningful medicines to help patients live longer"